Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
Hypersalivation (sialorrhea or ptyalism) is known as a frequent, disturbing, uncomfortable
adverse effect of clozapine therapy, and until now there is not enough effective treatment
for this side effect leading to noncompliance.
In previous studies it was found that substitute benzamide derivatives with higher selective
binding to the D2/D3 dopamine receptor - amisulpride and sulpiride may be effective in
treatment of clozapine-induced hypersalivation (CIH). Today, in psychiatric practice in
Israel, there are four medications which belong to substitute benzamide derivatives group:
amisulpride, sulpiride, tiapride and moclobemide. We hypothesized that antisalivation effect
is universal for the whole group of benzamide.
The aim of our study was to compare efficacy of amisulpride, moclobemide (reversible
monoamine oxidase inhibitor-A (RIMAS)), and tiapride (dopamine D2 antagonist) as an
additional possibility for management of CIH.